Neurocrine Biosciences (NBIX) Short Interest Ratio & Short Volume → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free NBIX Stock Alerts $139.83 -3.20 (-2.24%) (As of 05/2/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Neurocrine Biosciences Short Interest DataCurrent Short Volume2,020,000 sharesPrevious Short Volume2,430,000 sharesChange Vs. Previous Month-16.87%Dollar Volume Sold Short$266.11 millionShort Interest Ratio / Days to Cover2.3Last Record DateApril 15, 2024Outstanding Shares99,507,000 sharesPercentage of Shares Shorted2.03%Today's Trading Volume882,403 sharesAverage Trading Volume856,629 sharesToday's Volume Vs. Average103% Short Selling Neurocrine Biosciences ? Sign up to receive the latest short interest report for Neurocrine Biosciences and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatNBIX Short Interest Over TimeNBIX Days to Cover Over TimeNBIX Percentage of Float Shorted Over Time Ad Stansberry ResearchUrgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.Find out for free here. Neurocrine Biosciences Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20242,020,000 shares $266.11 million -16.9%N/A2.3 $131.74 3/31/20242,430,000 shares $335.15 million -2.0%N/A2.8 $137.92 3/15/20242,480,000 shares $344.97 million +13.8%N/A2.9 $139.10 2/29/20242,180,000 shares $284.27 million No ChangeN/A2.6 $130.40 2/15/20242,180,000 shares $292.12 million +16.0%N/A2.7 $134.00 1/31/20241,880,000 shares $262.77 million -18.6%N/A2.4 $139.77 Get the Latest News and Ratings for NBIX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. 1/15/20242,310,000 shares $304.99 million +1.8%N/A3.1 $132.03 12/31/20232,270,000 shares $299.10 million -0.4%N/A3.2 $131.76 12/15/20232,280,000 shares $274.10 million +8.1%N/A3.2 $120.22 11/30/20232,110,000 shares $246.00 million -7.5%N/A3.1 $116.59 11/15/20232,280,000 shares $252.42 million +2.2%N/A3.4 $110.71 10/31/20232,230,000 shares $247.40 million +1.8%N/A3.4 $110.94 10/15/20232,190,000 shares $247.12 million +18.4%N/A3.2 $112.84 9/30/20231,850,000 shares $208.13 million -8.4%N/A2.6 $112.50 9/15/20232,020,000 shares $227.15 million No ChangeN/A2.8 $112.45 8/31/20232,020,000 shares $219.96 million +3.6%N/A2.6 $108.89 8/15/20231,950,000 shares $207.32 million -3.9%N/A2.6 $106.32 7/31/20232,030,000 shares $206.84 million -12.9%N/A2.7 $101.89 7/15/20232,330,000 shares $221.61 million -3.7%N/A3.1 $95.11 6/30/20232,420,000 shares $228.21 million -5.1%N/A3.3 $94.30 6/15/20232,550,000 shares $246.97 million -1.9%N/A3.5 $96.85 5/31/20232,600,000 shares $232.78 million -6.8%N/A3.7 $89.53 5/15/20232,790,000 shares $273.84 million +5.7%N/A4 $98.15 4/30/20232,640,000 shares $266.75 million +3.5%N/A3.5 $101.04 4/15/20232,550,000 shares $262.09 million -7.6%N/A3.4 $102.78 3/31/20232,760,000 shares $279.37 million +3.4%N/A3.4 $101.22 3/15/20232,670,000 shares $251.27 million +5.1%N/A3.4 $94.11 2/28/20232,540,000 shares $261.87 million -1.6%N/A3.2 $103.10 2/15/20232,580,000 shares $267.62 million -1.2%N/A3.3 $103.73 1/31/20232,610,000 shares $289.53 million +0.8%2.8%3.2 $110.93 1/15/20232,590,000 shares $282.28 million +15.1%2.8%3.2 $108.99 12/30/20222,250,000 shares $268.74 million +0.5%2.4%2.8 $119.44 12/15/20222,240,000 shares $261.39 million -16.7%2.4%2.7 $116.69 11/30/20222,690,000 shares $341.79 million -5.3%2.9%3.3 $127.06 11/15/20222,840,000 shares $325.95 million +8.0%3.0%3.5 $114.77 10/31/20222,630,000 shares $302.77 million -4.0%2.8%3.3 $115.12 10/15/20222,740,000 shares $296.55 million +3.0%2.9%3.6 $108.23 9/30/20222,660,000 shares $282.52 million +10.4%2.8%3.6 $106.21 9/15/20222,410,000 shares $257.70 million +11.6%2.6%3.4 $106.93 8/31/20222,160,000 shares $226.00 million -21.7%2.3%3 $104.63Did You Get Your Free Bitcoin Yet? (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here NBIX Short Interest - Frequently Asked Questions What is Neurocrine Biosciences' current short interest? Short interest is the volume of Neurocrine Biosciences shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 2,020,000 shares of NBIX short. Learn More on Neurocrine Biosciences' current short interest. What is a good short interest ratio for Neurocrine Biosciences? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NBIX shares currently have a short interest ratio of 2.0. Learn More on Neurocrine Biosciences's short interest ratio. Which institutional investors are shorting Neurocrine Biosciences? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Neurocrine Biosciences: Concourse Financial Group Securities Inc., Simplex Trading LLC, Portman Square Capital LLP, Curated Wealth Partners LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Neurocrine Biosciences' short interest increasing or decreasing? Neurocrine Biosciences saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 2,020,000 shares, a drop of 16.9% from the previous total of 2,430,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Neurocrine Biosciences' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Neurocrine Biosciences: Repligen Co. (8.85%), Exelixis, Inc. (3.01%), Halozyme Therapeutics, Inc. (6.55%), Denali Therapeutics Inc. (8.33%), Adaptive Biotechnologies Co. (7.23%), Biogen Inc. (2.26%), Bio-Techne Co. (3.66%), Qiagen (1.34%), Vaxcyte, Inc. (7.58%), Revolution Medicines, Inc. (7.33%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Neurocrine Biosciences stock? Short selling NBIX is an investing strategy that aims to generate trading profit from Neurocrine Biosciences as its price is falling. NBIX shares are trading down $3.20 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Neurocrine Biosciences? A short squeeze for Neurocrine Biosciences occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NBIX, which in turn drives the price of the stock up even further. How often is Neurocrine Biosciences' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NBIX, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: RGEN Short Interest EXEL Short Interest HALO Short Interest DNLI Short Interest ADPT Short Interest BIIB Short Interest TECH Short Interest QGEN Short Interest PCVX Short Interest RVMD Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NBIX) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe AI stock to buy right nowStockEarningsCould Your Accounts Be Frozen?Allegiance GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithUrgent Nvidia WarningAltimetry$5,000 Gold?Stansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressYour bank is lying to you.MyBankTracker